FMRP 2016 | 1 Marc Bosiers Koen Deloose Joren Callaert A.Z. Sint-Blasius, Dendermonde Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist OLV Hospital, Aalst Lieven Maene Roel Beelen R.Z. Heilig Hart, Tienen Koen Keirse LINC Asia Pacific 2016, Hong Kong Combination therapy : treatment rationale and clinical evidence Koen Deloose, MD
30
Embed
A.Z. Sint-Blasius, Dendermonde Combination therapy : Joren ... · Physician-Initiated, prospective, multi-center (5), controled trial Investigating the Efficacy of EV Treatment of
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
FMRP 2016 | 1
Marc Bosiers Koen Deloose Joren Callaert
A.Z. Sint-Blasius, Dendermonde
Imelda Hospital, Bonheiden
Patrick Peeters Jürgen Verbist
OLV Hospital, Aalst
Lieven Maene Roel Beelen
R.Z. Heilig Hart, Tienen
Koen Keirse
LINC Asia Pacific 2016, Hong Kong
Combination therapy : treatment rationale and
clinical evidence
Koen Deloose, MD
FMRP 2016 |
DCB + Stent : treatment rationale
2
DCB
FMRP 2016|
Proof of concepts
3
DCB POBA
Sin
gle
arm
PASSEO 18 LUX
PTX 3µgr/mm²
+ BTHC
P=0.033
PACCOCATH
PTX 3µgr/mm² + Ultravist
P=0.031
IN.PACT
PTX 3µgr/mm²
+ Urea
P=0.001
CVI
PTX Excipient?
PACCOCATH
PTX 3µgr/mm² + Ultravist
P<0.001
LUTONIX
PTX 2µgr/mm²
+ polysorbate & sorbitol
P=0.016
ADVANCE
PTX 3µgr/mm²
No excipient
P=0.12
FMRP 2016|
Primary Patency at 12-months
4
N.A. N.A. N.A.
FMRP 2016|
Primary Patency at 12-months
5
N.A. N.A. N.A. 0
20
40
60
80
100
ste
nti
ng
rate
(%
)
stenting rate
FMRP 2016|
Freedom from TLR at 12-months
6
FMRP 2016|
Freedom from TLR at 12-months
7
0
20
40
60
80
100
ste
nti
ng
rate
(%
)
stenting rate
FMRP 2016|
Example Case of our daily practice
8
baseline Stenting
Pulsar 18 6mm (Biotronik°)
Dilatation Passeo 18 Lux 6mm
(Biotronik°)
1yr result
FMRP 2016|
Stents with PACLITAXEL work…
• ZILVER PTX versus ZILVER (COOK Medical®)
• ELUVIA versus INNOVA BMS (Boston Scientific®)
9
FMRP 2016|
BUT PTX footprint with DCB + BMS is bigger than DES…
10
DES PTX contact DCB + BMS PTX contact
FMRP 2016|
…and DCB + BMS is more adaptable…
• Longer lengths available (balloons – stents)
• Spot stenting – full coverage
• Economical advantage?
11
…DATA…
FMRP 2016|
DCB & Stent : clinical evidence
12
FMRP 2016|
DCB & Stent : clinical evidence
13 Liistro et al. JACC 2013;6(12):1295-1302
Single center, randomized trial
110 lesions : 55 DCB (IN.Pact Admiral) + BMS
((Maris SX) vs 55 POBA + BMS
Primary endpoint : 12 m binary restenosis
A.L.L. : 94 + 60 (DCB + BMS) vs 96 + 69 (POBA +
BMS)
FMRP 2016|
DCB & Stent : clinical evidence
14
120 patients – Target lesion < 19 cm
Primary endpoint : PPR @ 12 months DUS
(PSVR < 2,5)
Physician-Initiated, prospective, multi-center (5), controled trial Investigating the Efficacy of EV Treatment of Fempop Arterial Stenotic Disease with BIOtronik Passeo-18 LUX Drug Releasing Balloon & Biotronik
Pulsar-18 Stent (comparing with 4EVER trial results)